Total
0
Shares
Psyched Wellness (CSE:PSYC) initiates AME-1 extract study
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Psyched Wellness Ltd. (PSYC) has signed an agreement with KGK Science to study the anti-inflammatory nature of AME-1
  • KGK Science specializes in nutraceutical product testing and development and is leading the pre-clinical trials for Psyched
  • This new agreement will further advance the preliminary findings indicating an anti-inflammatory property
  • When gut health is damaged, it can lead to inflammation thus promoting a chronic condition of the gut lining
  • The aim of the study is to explore the anti-inflammatory properties of AME-1 extract
  • Psyched Wellness Ltd. (PSYC) is in the grey and is trading at C$0.30 at 1:31 pm ET

Psyched Wellness Ltd. (PSYC) has signed an agreement with its CRO partner, KGK Science to further study the anti-inflammatory nature of AME-1.

KGK Science specializes in nutraceutical product testing and development and is leading the pre-clinical trials for Psyched.

This new agreement will advance the preliminary findings indicating an anti-inflammatory property of the AME-1 extract.

This study will be the first to further explore the anti-inflammatory nature of the AME-1 extract from the Amanita Muscaria mushroom with a particular focus on gut health.

When gut health is damaged, it can lead to inflammation thus promoting a chronic condition of the gut lining and impairment of barrier function of the digestive tract.

The aim of the study is to explore the anti-inflammatory properties of AME-1 extract and demonstrate activities that may enhance digestive barrier function and immunity.

This is significant as gut health and immunity promotion are substantial for health and wellness.

"This is a key first step in the health and wellness studies of AME-1, which lay the groundwork for future preclinical research," said Brian Tancowny, scientific advisor to Psyched Wellness.

Psyched Wellness is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods.

Its objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. 

Psyched Wellness Ltd. (PSYC) is in the grey and is trading at C$0.30 at 1:31 pm ET.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

" Aurora Spine Corporation (TSXV:ASG) announces $6.5 million private placement

Aurora Spine Corporation (ASG) has announced a C$6.5 million private placement with institutional investors.